Business Context and Reporting Period
This Form 8-K is filed by OncoCyte Corporation (not Insight Molecular Diagnostics Inc.) on May 18, 2016. The filing serves to announce financial results for the three months ended March 31, 2016 and to notify investors of a conference call held on the same date to discuss these results and recent corporate developments.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were released in a press release (Exhibit 99.1) and discussed during a conference call, but the specific figures are not embedded in the 8-K text itself.
Material Changes
No material changes or comparative financial data versus prior periods are detailed in the text of this filing. The document references a press release for the explanation of financial and operating results.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks.
- Risk Factors: Investors are directed to the "Risk Factors" section of the company's Form 10 for additional factors that could cause actual results to differ materially from anticipated results.
- Outlook: No specific guidance or outlook figures are provided in this text; management commentary is contained in the referenced press release and conference call.
Important Facts for Investor Verification
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated May 18, 2016) referenced in this filing.
- Confirm the company name is OncoCyte Corporation, as the input metadata incorrectly listed "Insight Molecular Diagnostics Inc."
- Review the company's most recent Form 10 for detailed risk factors associated with forward-looking statements.
- Note that this 8-K is deemed "furnished" and not "filed" under the Securities Exchange Act of 1934.